Cassava Sciences, Inc. - SAVA STOCK NEWS

Cassava Sciences, Inc. (Nasdaq: SAVA) reported financial results for Q1 2022, revealing a net loss of $17.5 million, or $0.44 per share, up from a loss of $3.5 million, or $0.09 per share, in Q1 2021. Cash and cash equivalents stood at $209.7 million with no debt. The company is advancing its Phase 3 clinical program for simufilam in Alzheimer’s disease, now enrolling over 120 patients across 115 sites. R&D expenses rose significantly to $14.9 million due to increased clinical activities, while G&A expenses reached $2.9 million, primarily from legal services.

Cassava Sciences, a clinical-stage biotechnology company focused on Alzheimer’s disease, announced its participation in B. Riley Securities’ Neuroscience Conference on April 27-28, 2022. Remi Barbier, CEO, will engage in a Q&A session on April 27 at 1:30 PM ET. The event will be streamed live, with a recording available for 90 days post-event on both the conference site and Cassava Sciences’ investor webpage.

The company is currently advancing its lead drug candidate, simufilam, through Phase 3 clinical studies for Alzheimer’s treatment.

Cassava Sciences, Inc. (Nasdaq: SAVA) will hold a webcast on April 5, 2022, at 9 AM ET, featuring President & CEO Remi Barbier and CFO Eric Schoen. Stakeholders are invited to listen via the provided webcast link. Although there will be no live Q&A, participants can submit questions beforehand via email. The event will also have an archived replay available on the company's website for 90 days. Cassava focuses on developing treatments for Alzheimer’s disease, particularly their lead drug candidate, simufilam, currently in Phase 3 clinical trials.

Cassava Sciences, a clinical-stage biotechnology firm focusing on Alzheimer's disease, announced a Q1 2022 update via a fireside chat with CEO Remi Barbier on April 5, 2022, at 9 AM ET. The public can access the event through a webcast. Stakeholders are invited to submit questions in advance. Cassava is actively developing its lead drug, simufilam, currently in Phase 3 clinical studies under FDA guidelines, alongside various other studies to evaluate its efficacy for Alzheimer's treatment.

Cassava Sciences, Inc. (Nasdaq: SAVA) announced its financial results for 2021, reporting a net loss of $32.4 million ($0.82 per share), up from $6.3 million ($0.24 per share) in 2020. The firm has $233.4 million in cash, anticipating expenses of $25 to $35 million in H1 2022. In the second half of 2021, Cassava initiated two Phase 3 studies for its Alzheimer’s drug simufilam, aiming to enroll over 1,700 patients across North America. Research and development expenses surged to $24.8 million due to clinical trial costs, reflecting its commitment to tackling Alzheimer’s disease.

Cassava Sciences (Nasdaq: SAVA) announced the FDA's denial of multiple Citizen Petitions regarding allegations against the company. The petitions, filed by an attorney for short-selling clients, were dismissed, confirming the company's stance that the claims are false. Cassava is advancing its lead drug, simufilam, into Phase 3 clinical trials for Alzheimer’s, which are under Special Protocol Assessments by the FDA. Both trials are currently enrolling patients, marking significant progress in their Alzheimer's disease research.

Cassava Sciences announced the launch of Rethink-ALZ.com, a new clinical website aimed at enhancing visibility and information for participants in its Phase 3 studies of simufilam, an oral treatment for Alzheimer’s disease.

The site connects patients to nearby clinical sites and includes a pre-qualification questionnaire for potential participants. The Phase 3 studies, now active at over 25 clinical sites, aim to assess the efficacy of simufilam in approximately 1,750 patients across the U.S., Canada, and beyond.

Cassava Sciences (Nasdaq: SAVA) announced that the Neuroscience journal found no evidence of data manipulation in a 2005 article authored by the company. This clearance comes from an independent third party and reinforces the company’s stance against false allegations of scientific misconduct. Previously, the Journal of Neuroscience also cleared Cassava of similar accusations. The company continues testing its lead drug candidate, simufilam, for Alzheimer’s disease in Phase 3 clinical studies. Cassava emphasizes the importance of integrity in scientific research.

Cassava Sciences has initiated a second Phase 3 study of simufilam, its investigational drug for Alzheimer’s disease. This study, REFOCUS-ALZ, aims to evaluate the safety and efficacy of simufilam in about 1,000 patients over 78 weeks across the U.S. and Canada. Conducted under a Special Protocol Assessment from the FDA, the trial is a response to the growing need for effective Alzheimer’s treatments. Simufilam aims to restore the normal function of altered proteins in the brain, addressing underlying Alzheimer's pathology.